Ravulizumab has recently been approved by in the US for the treatment of adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Prof. Tuan Vu kindly joins touchNEUROLOGY to discuss the phase 3 CHAMPION-MG trial that evaluated the efficacy and safety of ravulizumab, a potent terminal complement C5 inhibitor, in AChR Ab+ gMG.
The abstract entitled ‘Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Study’ was presented at the American Academy of Neurology (AAN) Annual Meeting, April 2-7, 2022.
Questions:
1. What did the CHAMPION MG study teach us about ravulizumab’s efficacy and safety in patients with anti-acetylcholine receptor antibody-positive generalised MG? (0:12)
2. What were the study endpoints, and how well were they achieved? (1:31)
3. What is the current approval status of ravulizumab? (3:05)
4. On the basis of the CHAMPION MG findings what will be the impact of ravulizumab on the treatment of MG? (3:20)
Disclosures: Tuan Vu is a consultant for Alexion; and receives grant/research support from Alexion, UCB, argenx, Sanofi, Cartesian, Horizon, Regeneron, and Janssen; and is on the advisory board for Alexion, argenx, and UCB; and receives honoria/honorarium from Alexion, argenx, and UCB; and is a participant on the Speaker’s bueau for Alexion, and argenx.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
